FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097562914> ?p ?o ?g. }

• W2097562914 endingPage "2343" @default.
• W2097562914 startingPage "2343" @default.
• W2097562914 abstract "Thyroid malignancies have traditionally been under the care of endocrinologists. Thyroid cancer excellent prognosis, its unresponsiveness to conventional chemotherapy, and the specific and peculiar methods in the follow-up are some of the reasons for its particular management. Thyroid Cancer Guidelines have been published by Endocrine Societies both in the United States [1.Cooper D.S. Doherty G.M. Haugen B.R. et al.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid. 2009; 19: 1167-1214Crossref PubMed Scopus (5406) Google Scholar] and in Europe [2.Pacini F. Schlumberger M. Dralle H. European Thyroid Cancer Taskforce et al.European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.Eur J Endocrinol. 2006; 154: 787-803Crossref PubMed Scopus (1618) Google Scholar]. Furthermore, the adequate skills and knowledge related to running a good practice differ from the customary oncologic management. In fact, thyroid cancer is generally omitted from the oncology curriculum for oncologists’ residence education, whereas thyroid cancer management comprises a fundamental feature in the instruction of future endocrinologists. As a result, the oncologists’ experience and interest in the management of this particular type of cancer is generally scarce. We have read the position statement by the Spanish Society of Medical Oncology (SEOM) on the treatment of cancer with the new oral agents [3.Colomer R. Alba E. Gonzalez-Martin A. et al.Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology.Ann Oncol. 2010; 21: 195-198Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar]. We agree with the SEOM members that, for the benefit of our patients, ‘cancer treatment involves the participation of multiple medical specialties’. Our aim is to be collaborative rather than start a controversy. However, we remind that endocrinologists have led the introduction of these new oral drugs in the thyroid cancer treatment scenario [4.Duntas L.H. Bernardini R. Sorafenib: rays of hope in thyroid cancer.Thyroid. 2010; 20: 1351-1358Crossref PubMed Scopus (21) Google Scholar, 5.Ye L. Santarpia L. Gagel R.F. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.Endocr Rev. 2010; 31: 578-599Crossref PubMed Scopus (52) Google Scholar]. Clinical trials with tyrosine kinase inhibitors (TKI) for thyroid cancer patients have been at the beginning, and currently are, in the hands of endocrinologists [6.Sherman S.I. Wirth L.J. Droz J.P. Motesanib Thyroid Cancer Study Group et al.Motesanib diphosphate in progressive differentiated thyroid cancer.N Engl J Med. 2008; 359: 31-42Crossref PubMed Scopus (415) Google Scholar]. Therefore, we understand that endocrinologists must continue coordinating thyroid cancer patients’ management. Besides that, it is well described that TKI produce a number of endocrine side-effects such as hypothyroidism, which are especially relevant in the follow-up of these patients [5.Ye L. Santarpia L. Gagel R.F. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.Endocr Rev. 2010; 31: 578-599Crossref PubMed Scopus (52) Google Scholar]. As a parallel situation, we know that endocrinologists cannot claim for the exclusive use of any hormone-related drug. We fully understand that glucocorticoids, for instance, need to be widely used by oncologists and other specialists. Therefore, in agreement with the Spanish Society of Radiation Oncologist [7.Guedea F. Macia M. Sanchez Calzado J.A. et al.Treatment of cancer with drugs: a controversy (letter).Ann Oncol. 2011; 22: 747-748Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar], we consider that the statement of the SEOM has gone beyond the limits of desirable good relationship among different specialists. These authors declare no conflict of interest." @default.
• W2097562914 created "2016-06-24" @default.
• W2097562914 creator A5008994195 @default.
• W2097562914 creator A5011753898 @default.
• W2097562914 creator A5012095233 @default.
• W2097562914 creator A5012553683 @default.
• W2097562914 creator A5028779735 @default.
• W2097562914 creator A5034096555 @default.
• W2097562914 creator A5046616779 @default.
• W2097562914 creator A5046633406 @default.
• W2097562914 creator A5053160121 @default.
• W2097562914 creator A5065275037 @default.
• W2097562914 creator A5084673759 @default.
• W2097562914 creator A5090155183 @default.
• W2097562914 creator A5091004567 @default.
• W2097562914 date "2011-10-01" @default.
• W2097562914 modified "2023-09-26" @default.
• W2097562914 title "Treatment of thyroid cancer with the new oral agents" @default.
• W2097562914 cites W1966499183 @default.
• W2097562914 cites W2010117657 @default.
• W2097562914 cites W2037785144 @default.
• W2097562914 cites W2070563197 @default.
• W2097562914 cites W2116542352 @default.
• W2097562914 cites W2149600102 @default.
• W2097562914 cites W2163175491 @default.
• W2097562914 doi "https://doi.org/10.1093/annonc/mdr409" @default.
• W2097562914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21859897" @default.
• W2097562914 hasPublicationYear "2011" @default.
• W2097562914 type Work @default.
• W2097562914 sameAs 2097562914 @default.
• W2097562914 citedByCount "3" @default.
• W2097562914 countsByYear W20975629142012 @default.
• W2097562914 crossrefType "journal-article" @default.
• W2097562914 hasAuthorship W2097562914A5008994195 @default.
• W2097562914 hasAuthorship W2097562914A5011753898 @default.
• W2097562914 hasAuthorship W2097562914A5012095233 @default.
• W2097562914 hasAuthorship W2097562914A5012553683 @default.
• W2097562914 hasAuthorship W2097562914A5028779735 @default.
• W2097562914 hasAuthorship W2097562914A5034096555 @default.
• W2097562914 hasAuthorship W2097562914A5046616779 @default.
• W2097562914 hasAuthorship W2097562914A5046633406 @default.
• W2097562914 hasAuthorship W2097562914A5053160121 @default.
• W2097562914 hasAuthorship W2097562914A5065275037 @default.
• W2097562914 hasAuthorship W2097562914A5084673759 @default.
• W2097562914 hasAuthorship W2097562914A5090155183 @default.
• W2097562914 hasAuthorship W2097562914A5091004567 @default.
• W2097562914 hasBestOaLocation W20975629141 @default.
• W2097562914 hasConcept C121608353 @default.
• W2097562914 hasConcept C126322002 @default.
• W2097562914 hasConcept C143998085 @default.
• W2097562914 hasConcept C2779022025 @default.
• W2097562914 hasConcept C2779761222 @default.
• W2097562914 hasConcept C29456083 @default.
• W2097562914 hasConcept C512399662 @default.
• W2097562914 hasConcept C526584372 @default.
• W2097562914 hasConcept C71924100 @default.
• W2097562914 hasConceptScore W2097562914C121608353 @default.
• W2097562914 hasConceptScore W2097562914C126322002 @default.
• W2097562914 hasConceptScore W2097562914C143998085 @default.
• W2097562914 hasConceptScore W2097562914C2779022025 @default.
• W2097562914 hasConceptScore W2097562914C2779761222 @default.
• W2097562914 hasConceptScore W2097562914C29456083 @default.
• W2097562914 hasConceptScore W2097562914C512399662 @default.
• W2097562914 hasConceptScore W2097562914C526584372 @default.
• W2097562914 hasConceptScore W2097562914C71924100 @default.
• W2097562914 hasIssue "10" @default.
• W2097562914 hasLocation W20975629141 @default.
• W2097562914 hasLocation W20975629142 @default.
• W2097562914 hasOpenAccess W2097562914 @default.
• W2097562914 hasPrimaryLocation W20975629141 @default.
• W2097562914 hasRelatedWork W1966428911 @default.
• W2097562914 hasRelatedWork W2155240375 @default.
• W2097562914 hasRelatedWork W2172977592 @default.
• W2097562914 hasRelatedWork W2411783040 @default.
• W2097562914 hasRelatedWork W2519352624 @default.
• W2097562914 hasRelatedWork W2559080278 @default.
• W2097562914 hasRelatedWork W2795965551 @default.
• W2097562914 hasRelatedWork W2911382163 @default.
• W2097562914 hasRelatedWork W2989208471 @default.
• W2097562914 hasRelatedWork W4308141937 @default.
• W2097562914 hasVolume "22" @default.
• W2097562914 isParatext "false" @default.
• W2097562914 isRetracted "false" @default.
• W2097562914 magId "2097562914" @default.
• W2097562914 workType "article" @default.